Ann: Quarterly Activities Report and Appendix 4C, page-39

Hey mate

Been following this and biomed stuff for a while.

Walter Reed - that's only a study ON mice to ensure the results match - 16 mice each trial with blinds.

They aren't co-funding anything else. Or becoming a partner!

It should be noted that the trial has been cancelled until further notice as they have no staff to do it - which should tell you all you need to know about the importance they are placing on it. It will run for 6 months - already making it impossible that Phase I trials would start in Q4 2024 as claimed by the company.

Another thing some people seem to be missing is that NYR-BI03 is time-specific.

Just like the current treatment drug streptokinase there is only a small window of 60 - 70 minutes post brain injury to administer it or it simply doesn't work.

NYR-BI03 is also time specific.

Nyrada can do the phase I trial for sure - that's just to ensure NYR-BI03 doesn't make you drop dead as soon as you take it - that trial is in a years away at best!

Phase 2 & 3?

Not a hope.

It must be done in a major metro trauma centre - USA - to actually get access to traumatic brain injury victims within 70 mins.

That means a research and trial team needs to be there 24/7.

Appropriate medical staff 24/7

Nyrada cannot do this.

Walter Reed have no interest in doing this - all their patients are way past any use for a trial. The point of WR is to be a collaboration point for the US military to see if this potential drug NYR-BI03 can ever be suitable for battlefield medics.

The trauma trial hospital will look at it for CVA or trauma patients.

This will cost hundreds of millions of US dollars and take at least 8-10 years before it gets anywhere near the FDA.

If Walter Reed corroborates the trial results on mice, then the Phase 1 trial might be held in the next 24 - 36 months at best.

If they both look positive, then Nyrada gets bought out.

The way you are pumping it makes it sound like a big payday is around the corner!!

A partner will be needed for Stage 2 & 3.

It will be a big pharma and it will be a take-over as that is the only way a big pharma company will ever contemplate going forward with a tiny spec biomed company and invest $150,000,000+ USD.

It will be a simple takeover which Nyrada board will recommend. It won't be generous either. It will be a pittance compared to the drugs true worth if it does what it's supposed to.

It's horrible, but if Pharma want it - it will happen because the company cannot go anywhere without funding for trials.And without trials, they are dead in the water.

Probably worth thinking about when you are pumping the heck out of a company - it won't be a partnership, it will be a takeover .



You'd want to be long gone before the Sword Of Damocles appears.